Component

Human hepatic ATP measured by phosphorus MRS

Species, exposure, manipulation and evidence limits are specified on each linked claim.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Intravenous fructose acutely lowered hepatic ATP in seven healthy volunteers.

    Fructose → Human hepatic ATP measured by phosphorus MRS source_derived_draftungraded
    Experimental context and source evidence
    dose
    Fructose 250 mg/kg bolus
    duration
    Early 5 min changes; sugar-phosphate recovery within about 20 min
    evidence_access
    Primary abstract/metadata; unrecovered methods explicitly retained.
    evidence_scope
    literature_reviewed; source-specific curation
    experimental_model
    Seven healthy human volunteers
    exposure_scope
    Isolated fructose, intravenous
    limitations
    Injection bypasses the intestine. Magnitude cannot be assigned to a normal oral HFCS serving or to dietary phosphate deficiency.
    nutrient_topic
    HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
    organism
    Seven healthy human volunteers
    plain_language
    Intravenous fructose acutely lowered hepatic ATP in seven healthy volunteers.
    primary_references
    Assessment of human liver metabolism by phosphorus-31 magnetic resonance spectroscopy. (1986). https://pubmed.ncbi.nlm.nih.gov/3730768/ DOI: 10.1259/0007-1285-59-703-695
    route
    Intravenous injection
    tissue
    Liver phosphorus-31 MRS

    High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 233–243

    Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Seven healthy human volunteers · source_derived_draft · unverified_draft

    ## hfcs-iv-atp Intravenous fructose acutely lowered hepatic ATP in seven healthy volunteers. Model/species: Seven healthy human volunteers Tissue: Liver phosphorus-31 MRS Exposure: Fructose 250 mg/kg bolus Route: Intravenous injection Duration: Early 5 min changes; sugar-phosphate recovery within about 20 min Exposure scope: Isolated fructose, intravenous Limits: Injection bypasses the intestine. Magnitude cannot be assigned to a normal oral HFCS serving or to dietary phosphate deficiency. Reference: Assessment of human liver metabolism by phosphorus-31 magnetic resonance spectroscopy. (1986). https://pubmed.ncbi.nlm.nih.gov/3730768/ DOI: 10.1259/0007-1285-59-703-695 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
    Complete structured claim and evidence

  2. After 75 g oral fructose, hepatic ATP decreased within 15 minutes and remained lower at 60 minutes in participants without MASLD.

    Fructose → Human hepatic ATP measured by phosphorus MRS source_derived_draftungraded
    Experimental context and source evidence
    dose
    75 g fructose challenge
    duration
    60 min
    evidence_access
    Primary abstract/metadata; unrecovered methods explicitly retained.
    evidence_scope
    literature_reviewed; source-specific curation
    experimental_model
    37 overweight/obese adults without diabetes, stratified by MASLD
    exposure_scope
    Isolated fructose, oral
    limitations
    Small acute component study; the ATP response was blunted in MASLD, not uniformly greater. Metabolite signals are not chronic clinical outcomes.
    nutrient_topic
    HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
    organism
    37 overweight/obese adults without diabetes, stratified by MASLD
    plain_language
    After 75 g oral fructose, hepatic ATP decreased within 15 minutes and remained lower at 60 minutes in participants without MASLD.
    primary_references
    Patients with MASLD exhibit in vivo changes in hepatic response to oral fructose consumption. (2026). https://pubmed.ncbi.nlm.nih.gov/41866318/ DOI: 10.1210/clinem/dgag125
    route
    Oral solution
    tissue
    Liver phosphorus-31 MRS

    High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 257–267

    Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 37 overweight/obese adults without diabetes, stratified by MASLD · source_derived_draft · unverified_draft

    ## hfcs-oral-atp After 75 g oral fructose, hepatic ATP decreased within 15 minutes and remained lower at 60 minutes in participants without MASLD. Model/species: 37 overweight/obese adults without diabetes, stratified by MASLD Tissue: Liver phosphorus-31 MRS Exposure: 75 g fructose challenge Route: Oral solution Duration: 60 min Exposure scope: Isolated fructose, oral Limits: Small acute component study; the ATP response was blunted in MASLD, not uniformly greater. Metabolite signals are not chronic clinical outcomes. Reference: Patients with MASLD exhibit in vivo changes in hepatic response to oral fructose consumption. (2026). https://pubmed.ncbi.nlm.nih.gov/41866318/ DOI: 10.1210/clinem/dgag125 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
    Complete structured claim and evidence

  3. Participants with MASLD showed a blunted ATP response to oral fructose, with only a nonsignificant early drop and recovery by 30 minutes.

    Fructose → Human hepatic ATP measured by phosphorus MRS source_derived_draftungraded
    Experimental context and source evidence
    dose
    75 g fructose challenge
    duration
    60 min
    evidence_access
    Primary abstract/metadata; unrecovered methods explicitly retained.
    evidence_scope
    literature_reviewed; source-specific curation
    experimental_model
    37 overweight/obese adults without diabetes, stratified by MASLD
    exposure_scope
    Isolated fructose, oral
    limitations
    Small acute component study; the ATP response was blunted in MASLD, not uniformly greater. Metabolite signals are not chronic clinical outcomes.
    nutrient_topic
    HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
    organism
    37 overweight/obese adults without diabetes, stratified by MASLD
    plain_language
    Participants with MASLD showed a blunted ATP response to oral fructose, with only a nonsignificant early drop and recovery by 30 minutes.
    primary_references
    Patients with MASLD exhibit in vivo changes in hepatic response to oral fructose consumption. (2026). https://pubmed.ncbi.nlm.nih.gov/41866318/ DOI: 10.1210/clinem/dgag125
    route
    Oral solution
    tissue
    Liver phosphorus-31 MRS

    High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 269–279

    Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 37 overweight/obese adults without diabetes, stratified by MASLD · source_derived_draft · unverified_draft

    ## hfcs-oral-atp-masld Participants with MASLD showed a blunted ATP response to oral fructose, with only a nonsignificant early drop and recovery by 30 minutes. Model/species: 37 overweight/obese adults without diabetes, stratified by MASLD Tissue: Liver phosphorus-31 MRS Exposure: 75 g fructose challenge Route: Oral solution Duration: 60 min Exposure scope: Isolated fructose, oral Limits: Small acute component study; the ATP response was blunted in MASLD, not uniformly greater. Metabolite signals are not chronic clinical outcomes. Reference: Patients with MASLD exhibit in vivo changes in hepatic response to oral fructose consumption. (2026). https://pubmed.ncbi.nlm.nih.gov/41866318/ DOI: 10.1210/clinem/dgag125 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards